960116-27-2

Usage

Uses

Used in Pharmaceutical Research:
Ethyl 5-(tetraMethyl-1,3,2-dioxaborolan-2-yl)thiophene-3-carboxylate is used as a key intermediate in the synthesis of new drugs. Its unique structure and functional groups contribute to the development of pharmaceutical compounds with potential therapeutic applications.
Used in Organic Synthesis:
ethyl 5-(tetraMethyl-1,3,2-dioxaborolan-2-yl)thiophene-3-carboxylate serves as a versatile building block in organic synthesis, enabling the creation of a wide range of chemical products. Its reactivity and functional groups facilitate the formation of new chemical entities with diverse applications.
Used in Agrochemical Development:
Ethyl 5-(tetraMethyl-1,3,2-dioxaborolan-2-yl)thiophene-3-carboxylate is utilized in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural products that enhance crop protection and yield.
Used in Advanced Materials:
ethyl 5-(tetraMethyl-1,3,2-dioxaborolan-2-yl)thiophene-3-carboxylate's unique properties also make it suitable for the development of advanced materials with specific characteristics, such as high-performance polymers, sensors, or other innovative materials with potential applications in various industries.

Upstream product

• 170355-38-1 5-bromo-3-thiophenecarboxylic acid ethyl ester 
• 73183-34-3 bis(pinacol)diborane 
• 5751-80-4 thiophene-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Iridium-Catalyzed Silylation of Five-Membered Heteroarenes: High Sterically Derived Selectivity from a Pyridyl-Imidazoline Ligand

The steric effects of substituents on five-membered rings are less pronounced than those on six-membered rings because of the difference in bond angles. Thus, the regioselectivities of reactions of five-membered heteroarenes that occur with selectivities dictated by steric effects, such as the borylation of C?H bonds, have been poor in many cases. We report that the silylation of five-membered-ring heteroarenes occurs with high sterically derived regioselectivity when catalyzed by the combination of [Ir(cod)(OMe)]2 (cod=1,5-cyclooctadiene) and a phenanthroline ligand or a new pyridyl-imidazoline ligand that further increases the regioselectivity. The silylation reactions with these catalysts produce high yields of heteroarylsilanes from functionalization at the most sterically accessible C?H bonds of these rings under conditions that the borylation of C?H bonds with previously reported catalysts formed mixtures of products or products that are unstable. The heteroarylsilane products undergo cross-coupling reactions and substitution reactions with ipso selectivity to generate heteroarenes that bear halogen, aryl, and perfluoroalkyl substituents.

IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds of formula (I) as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.